PsyBio Therapeutics Corp
PsyBio Therapeutics Corp., a biotechnology company, engages in the research, development, and commercialization of psychedelic-inspired regulated medicines for the treatment of mental health and other disorders in the United States. PsyBio Therapeutics Corp. was formerly known as Leo Acquisitions Corp. and changed its name to PsyBio Therapeutics Corp. in January 2021. The company was incorporated… Read more
PsyBio Therapeutics Corp (PSYBF) - Net Assets
Latest net assets as of June 2023: $-1.69 Million USD
Based on the latest financial reports, PsyBio Therapeutics Corp (PSYBF) has net assets worth $-1.69 Million USD as of June 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($283.14K) and total liabilities ($1.97 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.69 Million |
| % of Total Assets | -596.0% |
| Annual Growth Rate | N/A |
| 5-Year Change | -1158.9% |
| 10-Year Change | N/A |
| Growth Volatility | 259.42 |
PsyBio Therapeutics Corp - Net Assets Trend (2016–2022)
This chart illustrates how PsyBio Therapeutics Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PsyBio Therapeutics Corp (2016–2022)
The table below shows the annual net assets of PsyBio Therapeutics Corp from 2016 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $-1.59 Million | -158.54% |
| 2021-12-31 | $2.72 Million | +468.79% |
| 2020-12-31 | $-736.91K | -675.75% |
| 2019-12-31 | $127.99K | -14.81% |
| 2018-12-31 | $150.25K | -11.61% |
| 2017-12-31 | $169.97K | +7.22% |
| 2016-12-31 | $158.53K | -- |
Equity Component Analysis
This analysis shows how different components contribute to PsyBio Therapeutics Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2139850400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $16.88 Million | % |
| Other Comprehensive Income | $3.18 Million | % |
| Other Components | $156.41K | % |
| Total Equity | $-1.59 Million | 100.00% |
PsyBio Therapeutics Corp Competitors by Market Cap
The table below lists competitors of PsyBio Therapeutics Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NCR (NIGERIA) PLC
XNSA:NCR
|
$1.28K |
|
SAFEROADS HLDGS
BE:S4Q
|
$1.28K |
|
Catalyst Media Group PLC
LSE:CMX
|
$1.28K |
|
LUPA3F
SA:LUPA3F
|
$1.28K |
|
Lode Gold Resources Inc.
OTCQB:SBMID
|
$1.27K |
|
JAPFA COMFEED -A-
BE:1JC1
|
$1.27K |
|
CONS
NSE:CONS
|
$1.27K |
|
ROCA INDUSTRY HOLDINGROCK1 S.A.
RO:ROC1
|
$1.27K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PsyBio Therapeutics Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 2,717,666 to -1,590,942, a change of -4,308,608 (-158.5%).
- Net loss of 4,886,000 reduced equity.
- Share repurchases of 88,103 reduced equity.
- New share issuances of 156,410 increased equity.
- Other comprehensive income increased equity by 509,148.
- Other factors decreased equity by 63.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.89 Million | -307.11% |
| Share Repurchases | $88.10K | -5.54% |
| Share Issuances | $156.41K | +9.83% |
| Other Comprehensive Income | $509.15K | +32.0% |
| Other Changes | $-63.00 | -0.0% |
| Total Change | $- | -158.54% |
Book Value vs Market Value Analysis
This analysis compares PsyBio Therapeutics Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $0.11 | $0.00 | x |
| 2017-12-31 | $0.07 | $0.00 | x |
| 2018-12-31 | $0.06 | $0.00 | x |
| 2020-12-31 | $-0.02 | $0.00 | x |
| 2021-12-31 | $0.03 | $0.00 | x |
| 2022-12-31 | $-0.01 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PsyBio Therapeutics Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-70.18%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -35.87% | 0.00% | 0.00x | 1.61x | $-72.71K |
| 2017 | -23.45% | 0.00% | 0.00x | 1.21x | $-56.85K |
| 2018 | -13.88% | 0.00% | 0.00x | 1.29x | $-35.89K |
| 2019 | -12.62% | 0.00% | 0.00x | 1.26x | $-28.96K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.36 Million |
| 2021 | -405.45% | 0.00% | 0.00x | 1.47x | $-11.29 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.73 Million |
Industry Comparison
This section compares PsyBio Therapeutics Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PsyBio Therapeutics Corp (PSYBF) | $-1.69 Million | -35.87% | N/A | $1.27K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |